RE:RE:Laurie, Ciao and Used ProphylacticYears ago before the BNN hype, Ceapro was struggling as a company. The share price was in the .05 to .10 range and didn't start to get any traction till revenues started to move up consistently. In 2014 they licenced PGX. I don't know what the exact daily volume was in 2014 but it was more similar to what it is now vs the BNN hype period.
Two of the 3 persons who hyped up CZO no longer are guests on BNN. There were are least 2 guests who commented on viewers questions and had cautionary warnings based on valuation. Those wanting to see a similar feeding frenzy stoked by BNN personalities in the same magnitude as 2016 will forever be disappointed.
The fundamentals of the company is the best it has ever been and it's been argued it can support a much higher share price. What we need is an IR strategy that can get the story out to Canadian retail investors and capture their interest. If investors want to speculate on the first licencing deal, say on the functional drink with a new iteration of a PGX substrate(s) with the recent bioavailability results, this would be a more favorable time at .70 share vs $2 during the BNN hype.